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Previewsmelanoma) progression with regard to
OIS, a topic with significance for many
cancer types beyond melanoma.REFERENCES
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In this issue ofCancer Cell, Schwartz and colleagues andCosta and colleagues demonstrate that inhibition of
PI3Ka or PI3Kb in cancer cells with hyperactivated PI3Ka or PI3Kb, respectively, activates the other isoform,
leading to a ‘‘rebound’’ of the PI3K activity through different compensation mechanisms.Phosphoinositide 3-kinases (PI3Ks) con-
tribute to many cellular processes, in-
cluding cell growth, survival, migration
and stress responses, cell cycle progres-
sion, and intracellular vesicular transport
(Vanhaesebroeck et al., 2012). At the
plasma membrane, PI3Ks catalyze the
production of 3-phosphoinositides that
coordinate the localization and activation
of lipid-binding proteins such as Akt ki-
nase. Activated Akt modulates the func-
tion of numerous substrates involved in
the regulation of cell survival and growth
as well as cell cycle progression.
There are three classes of PI3Ks that
differ in structure and function (Vanhaese-
broeck et al., 2010). Class I PI3Ks, which
are the best studied, are heterodimers
composed of a regulatory subunit (often
referred to as p85) and one of four
catalytic subunits (p110a, b, d, and g).
Although PI3K isoforms have highlysimilar structures and enzymatic activ-
ities, they have differing, nonredundant
functions.
Given the key role of PI3K in important
biological processes, it is not surprising
that the PI3K/Akt signaling cascade is
one of the most frequently altered path-
ways in human cancers. Oncogenic
activation of PI3K results from somatic
mutation/amplification of PIK3CA encod-
ing the p110a subunit, loss of the PI3K
negative regulator PTEN, mutation/ampli-
fication of various upstream signaling
components, or other nongenetic mecha-
nisms. The oncogenicity of p110a
has recently attracted much attention,
because large-scale genomic studies
have revealed that PIK3CA is the most
commonly mutated oncogene in many
cancer types (Lawrence et al., 2014).
Although non-a PI3K isoforms are less
frequently mutated, experimental datasupport their oncogenic potential (Kang
et al., 2006).
The identification and development of
PI3K inhibitors as anticancer therapies
has proceeded rapidly over the last few
years. Both isoform-specific and non-
specific (‘‘pan-PI3K inhibitors’’) inhibitors
have been generated. These agents,
which include compounds with varying
degrees and combinations of isoform
specificity, have been intensively exam-
ined in a large number of early phase clin-
ical trials (Rodon et al., 2013). In solid
tumors, themost advanced of these com-
pounds have entered or completed enrol-
ment of randomized phase III trials, the
results of which are eagerly awaited.
However, despite the early excitement
around the potential for this targeted ther-
apeutic strategy, clinical activity has been
less dramatic than anticipated, and the
therapeutic index of some of these PI3K27, January 12, 2015 ª2015 Elsevier Inc. 5
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Figure 1. The Rebound Effect of Isoform-Specific PI3K Inhibitors
Costa et al. (2015) showed that human luminal breast cancer cells withHER2 amplification or PI3KCAmu-
tation mostly rely on PI3Ka activity to control Akt activation. Indeed, PI3Ka inhibition by BYL719 tempo-
rarily reduces Akt phosphorylation and PIP3 levels before a rebound effect on the PI3Kb isoform takes
place. Here, PI3Kb activation is a consequence of increased expression of the ERBB3 receptor. Similarly,
Schwartz et al. (2015) showed that breast and prostate cancer cells with inactivating mutations of PTEN
(mPTEN) mainly depend on the PI3Kb isoform. Use of a PI3Kb-specific inhibitor such as AZD8186 initially
suppresses Akt activation. Akt is restored when PI3Ka is positively regulated by insulin-like growth factor
receptor 1 (IGF1R). Both reports support the conclusion that concomitant inhibition of PI3Ka and PI3Kb
isoforms is necessary to efficiently suppress the growth of cancers exhibiting oncogenic PI3K activation.
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understanding of why and how these
compounds work or fail is thus of critical
importance and could have a significant
impact on refining therapeutic strategies
to achieve optimal clinical results. In this
issue of Cancer Cell, Schwartz et al.
(2015) and Costa et al. (2015) identify
and characterize several mechanisms
that restrict the ability of isoform-specific
PI3K inhibitors when used as monother-
apy to achieve PI3K/Akt pathway inhibi-
tion and antitumor activity.
Schwartz et al. (2015) showed that the
PI3Kb isoform inhibitor AZD8186 only
transiently suppressed the oncogenic
hyperactivation of PI3K signaling in
PTEN-deficient human breast and pros-
tate cancer cells. Although the PI3K
pathway was acutely inhibited at 30 min
posttreatment, PI3K signaling was gradu-
ally restored over two hours, as docu-
mented by the phosphorylation of Akt
itself and that of its substrate, PRAS40.
These authors showed that this rebound
of Akt signaling depended on the activa-
tion of the PI3Ka isoform (Figure 1). Co-
treatment of cells with AZD8186 plus
BYL719, a PI3Ka isoform inhibitor, mark-6 Cancer Cell 27, January 12, 2015 ª2015 Eledly attenuated Akt phosphorylation.
These data suggest that, at least in these
cancer cells, the activity of the PI3Ka
isoform was initially low but steadily
increased in response to b isoform inhibi-
tion. Indeed, only when a combination of
PI3Ka and PI3Kb isoform inhibitors was
used to treat either breast or prostate can-
cer cells was tumor cell growth efficiently
suppressed and apoptosis induced. The
authors analyzed the mechanism of reac-
tivation of the PI3Ka isoform in AZD8186-
treated cells and found that this agent
increased the expression of IGF1R/insulin
receptor substrate (IRS1) proteins, which
are potent activators of PI3K signaling.
Combined treatment with the IGF1R/IR
inhibitor OSI-906 significantly attenuated
the rebound of Akt activation induced by
AZD8186 treatment. These results sug-
gest that inhibition of both the a and b
isoforms of PI3K, either directly or via tar-
geting of induced feedback loops, is
necessary for sustained inhibition of
PI3K signaling and antitumor activity in
PTEN null cancer cells (Figure 1).
The work described by Costa and col-
leagues arrives at a similar conclusion
(Costa et al., 2015). In this study, the au-sevier Inc.thors used BYL719 to inhibit the PI3Ka
isoform in human luminal breast cancer
cells with ERBB2 (HER2) amplification
or PIK3CA-activating mutations. BYL719
initially abrogated PI3K signaling in the
treated cells, as evidenced by their low
Akt activity. Reminiscent of the effect
observed by Schwartz et al. (2015), after
24 h, the BYL719-treated cells showed a
rebound increase in the phosphoinositide
PIP3 (Figure 1). In PIK3CA mutated cell
lines, however, this occurred in the
absence of Akt activation. These findings
highlight a potential pitfall in the use of Akt
phosphorylation as a pharmacodynamic
biomarker of PI3K activation and suggest
the possibility that monitoring PIP3 levels
provide a more accurate readout of
PI3K/Akt pathway activity. Further anal-
ysis revealed that the elevation in PIP3
levels was due to an increase in the
recruitment of the PI3Kb isoform to the
ERBB3 receptor. As in the scenario exam-
ined by Schwartz et al. (2015), co-treat-
ment of breast cancer cells with both a
and b isoform inhibitors significantly
enhanced cancer cell death and induced
tumor regression in vivo (Figure 1).
While evaluation of the generalizability
of these observations in additional con-
texts is necessary, the results of these
two papers have important implications
for the development of clinical strategies
involving the use of PI3K inhibitors. They
suggest that inhibition of both a and b
isoforms will be necessary to achieve
maximal antitumor activity: whether com-
binations of a- and b-specific inhibitors
will have a greater therapeutic index
than the currently available pan-PI3K in-
hibitors remains to be seen. In addition,
these works indicate the need to further
examine the feedback pathways resulting
from single-isoform inhibition and study
combination strategies that can interrupt
these rebound effects. However, data
from early phase clinical trials of single-
isoform inhibitors have suggested that
combined inhibition is not always
required. Additional characterization of
the intricate feedback mechanisms regu-
lating the PI3K/Akt pathway may help to
identify tumors susceptible to individual
isoform inhibition and may reveal whether
this vulnerability is due to an inability to
mount a feedback response. The dynamic
nature of these feedback responses rai-
ses two other important questions. (1)
Could discontinuous dosing strategies
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mizing feedback activation of the parallel
pathway? (2) Do our preclinical systems,
where drugs are often tested in vitro for
short periods of time, provide a reliable
measure of antitumor effect when feed-
back activation occurs on this timescale?
Along with the recent genetic evidence
from tumors acquiring resistance to
BYL719 (Juric et al., 2014), the findings
of Schwartz et al. (2015) and Costa et al.
(2015) underscore the fact that tumors
can and will maintain PI3K activation
through a variety of mechanisms in the
face of pharmacologic inhibitors. Our
ability to devise the right combinations of
PI3K isoform inhibitors, or to select the
right subgroup of patientswho can benefitfrom these agents without suffering intol-
erable toxicities, will determine the ulti-
mate clinical impact of this class of drugs.
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In this issue of Cancer Cell, Wong and colleagues describe a novel approach of increasing the number
of functional blood vessels in tumors using a low-dose therapy regimen of Cilengtide and Verapamil.
This method enhanced Gemcitabine delivery, uptake, and metabolism within tumor cells to reduce tumor
growth and progression.The development of new blood vessels
from preexisting vessels is a multifaceted
process known as angiogenesis and a
well-established ‘‘hallmark of cancer’’.
The wealth of proangiogenic molecules
produced by tumor and stroma cells
induces angiogenesis, remodelling of the
vasculature, and recruitment of many
types of lymphoid and myeloid cells as
well as endothelial progenitors. The tumor
vasculature thus differs markedly from
normal vessels, is a key route for metas-
tasis, and is essential for nutrient and
metabolite exchange.
The concept of controlling metastatic
tumors by targeting tumor blood supply
was first proposed in the early 1970s,
and, since then, many drugs targetingblood vessels have been developed
(Figure 1); most specifically inhibit
vascular endothelial growth factor (VEGF)
A function, a major proangiogenic mole-
cule in cancer (Bridges and Harris, 2011).
They have, in several tumor types, a major
therapeutic role, in others a more ancillary
effect. Antiangiogenic therapy has
increased progression-free survival of pa-
tients with many cancers, but resistance
results in antiangiogenic therapy having
little impact on overall survival.
During antiangiogenic treatment (Fig-
ure 1A), a temporary window of opportu-
nity occurs when therapy re-balances
the pro- and antiangiogenic signals to
the point that vessels become more
‘‘natural’’ with improved blood flow intumor regions previously poorly perfused
being observed, referred to as tumor
vasculature normalization (Jain, 2014).
Increased chemotherapy delivery to the
tumor occurs during this short time frame
with improved drug uptake and reduced
side effects observed (Batchelor et al.,
2013). However, the duration of vascular
normalization is time- and dose-depen-
dent, and the onset varies between
patients.
Another mechanism targeting tumor
vasculature is the development of
vascular-disrupting agents that induce
endothelial cell death by disrupting their
cytoskeleton and adhesion to matrix and
activating local coagulation (Figure 1B).
Thus vascular-disrupting agents result27, January 12, 2015 ª2015 Elsevier Inc. 7
